2022. Delaying the Onset of Type 1 Diabetes with Teplizumab: A Narrative Review of Autoantibody Screening and Who Would Actually Be Treated. Journal of Clinical Diabetes and Obesity. 2, 1 (Oct. 2022), 7–12. DOI:https://doi.org/10.5281/zenodo.22238844.